Home
OLV Overview
The Office of Licensing & Ventures (OLV) is responsible for patents, technology licenses and new venture development for Duke University and Medical Center. Through direct, daily interaction with faculty, small and large businesses, and venture investors, we build strong relationships and strong agreements to translate academic discoveries into commercial products that benefit society, impact public health, and improve the quality of life.
Featured Technologies
Novel antimicrobial compounds for treating Gram-negative infections
Personalized, Multiple Behavior and Medication Management Intervention for Chronic Disease
Latest News
Trevena, Inc. and Forest Laboratories Announce a Collaborative Agreement For Development of TRV027 for the Treatment of Acute Heart Failure
May 9, 2013
Forest Laboratories leads Trevena's $60 Million Series C Funding Round; All existing investors to also participate
Trevena to present first-in-man study results for mu-opioid biased ligand TRV130
March 18, 2013
Poster at the 2013 AAN meeting describes the human safety and
pharmacology of intravenous analgesic TRV130 in healthy volunteers.
Trevena GPCR platform yields a novel mu-opioid biased ligand analgesic with side effect benefits
January 23, 2013
JPET publication describes the discovery and activity of TRV130
Regado Biosciences, Inc. Secures $51 Million Series E Financing
December 17, 2012
New Investor Leads Round to Fund Phase 3 Development of REG1
Precision BioSciences Announces First Publication of Targeted Knockout Rats Using Engineered Meganuclease Technology
December 11, 2012
Enables development of complex disease models
Precision BioSciences Announces Publication of Cotton Trait Stacking Success in Collaboration with Bayer CropScience
November 26, 2012
Herbicide Tolerance Gene Precisely Inserted Adjacent to Insect Resistance Gene using Site-Specific Genome Editing Technology
Trevena Completes FTIH Study of TRV130, an Injectable Mu-Opioid Biased Ligand for Acute Pain
November 14, 2012
TRV130 is generally well-tolerated and rapidly enters the CNS in healthy adult males.
Celsion Corporation Reports Third Quarter 2012 Financial Results and Business Update
November 12, 2012
Celsion Announces Phase III HEAT Study of ThermoDox(R) in Primary Liver Cancer Reaches Target Number of Events for Unblinding
November 9, 2012
Company Begins Data Collection, Expects to Report Top Line Data in January 2013; Reiterates Strong Balance Sheet Position
Faster decisions at the cutting edge
October 15, 2012
Cambridge Consultants partners with HemoSonics on diagnostic instrument development for blood clotting disorders
Trevena, Inc. Founder Wins Nobel Chemistry Prize
October 10, 2012
The 2012 Nobel Prize for Chemistry has been awarded to Robert Lefkowitz and Brian Kobilka for their work on the G-protein coupled receptor system and its application in medical science.
Trevena Completes Phase 2a Study of TRV027 in Patients with Advanced Heart Failure
October 8, 2012
TRV027 improves hemodynamics and is well-tolerated in patients with stable advanced heart failure, supporting advancement into a Phase 2b study in ADHF
CellepathicRx Partners with Leading Academic Medical Center on mHealth Mobile Platform with Research-Backed Behavioral Content
October 4, 2012
TeraDiscoveries Announces the Design of Six New Drugs In-Silico as Part of Strategic Relationship
June 14, 2012
GrassRoots Biotechnology and Monsanto extend research collaboration
September 27, 2011
GrassRoots Biotechnology and Monsanto extend research collaboration
Celsion Announces Issuance of U.S. Patent Covering ThermoDox(R) Technologies
April 13, 2011
New Patent Extends U.S. Intellectual Property Protection of ThermoDox(R) and Other Temperature-Sensitive Liposomal Formulations to 2021
Celsion Receives COMP Recommendation for Orphan Drug Designation in Europe for ThermoDox® to Treat Primary Liver Cancer
November 11, 2010
Cellona Therapeutics, Inc. Awarded Qualifying Therapeutic Discovery Project (QTDP) Grant for CT-10 Novel Targeted Cancer Compound
November 3, 2010
Cellona Therapeutics, Inc. and Duke Announce Exclusive Licensing Agreement and Collaboration to Develop Novel Cancer Drugs
September 14, 2010
Trevena Secures $35 Million in Series B Funding
July 14, 2010
Argos Therapeutics Presents Positive Phase 2 Data for Arcelis™ Dendritic Cell-based Immunotherapy in Advanced RCC at ASCO
June 8, 2010
-Interim Data in Combination with Sunitinib Demonstrate Positive Clinical Activity-
GrassRoots selected to participate in NCBC Industrial Fellowship Program
April 22, 2010
Trevena Initiates Clinical Development of TRV120027, a First-in-Class Biased Ligand
April 14, 2010
Bioptigen, Inc. Receives 2008 Frost & Sullivan North America
March 10, 2010
PhaseBio Pharmaceuticals, Inc. Raises $25 Million in Series B Funding, Initiates Collaboration with OSI Pharmaceuticals
January 7, 2010
REGADO BIOSCIENCES, INC. COMPLETES $40 MILLION SERIES D FINANCING
December 17, 2009
Trevena Awarded $7.65 Million NIH Grant
November 3, 2009
Aerie Pharmaceuticals’ ROCK Inhibitor, AR-12286, Demonstrates Positive Results in Glaucoma Patients in a Phase 2a Study
October 22, 2009
Novel Drug has Potential to Create Significant Improvement in Function of Diseased Tissue
Centice Corporation closes on $6.1 million Series C financing
October 21, 2009
Funds to support commercialization of innovative PASS Rx® system